Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase 1/2 4Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 5Terminated 4Completed 4Withdrawn 3

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Head & Neck 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neuroblastoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Breast Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × copanlisib × Clear all
NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
2 enrolled 6 charts
Breast

Breast Neoplasms

NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT02535247 2022-07-08

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Fox Chase Cancer Center

Phase 1/2 Terminated
17 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02822482 2021-03-29

COPAN-ORL06

UNICANCER

Phase 1/2 Terminated
11 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡